Corbus Pharmaceuticals announces clinical data for CRB-701

Corbus Pharmaceuticals (CRBP) announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe of CRB-701 has been released. The corresponding up-to-date data will be presented as a poster during the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium. The data from 31 patients referred to in the abstract dates to September 2024; the upcoming poster presentation will include data on 38 patients as of December 2024. ASCO GU will be held in San Francisco, CA February 13-15, 2025. The abstract, Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 in US And UK Patients with Urothelial Cancer and other Solid Tumors will be presented on Friday February 14, 202. The three-part Phase 1 Western study is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the study evaluated four predetermined doses and is followed by Part B and Part C that will determine recommended/optimized doses and seek preliminary efficacy signals.